Halozyme Therapeutics HALO Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's stock-based comp?
- Halozyme Therapeutics (HALO) reported stock-based comp of $16.64M in Q1 2026.
- How has Halozyme Therapeutics's stock-based comp changed year-over-year?
- Halozyme Therapeutics's stock-based comp increased by 55.9% year-over-year, from $10.67M to $16.64M.
- What is the long-term trend for Halozyme Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's stock-based comp has grown at a 25.4% compound annual growth rate (CAGR), from $20.82M to $51.57M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.